Atlas Legacy Advisors’s Thermo Fisher Scientific TMO Stock Holding History

Atlas Legacy Advisors’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-430	Closed	-$211K	–	223
2026 Q1	$211K	Sell	430 -213	-33%	-$116K	0.04%	187
2025 Q4	$383K	Buy	643 +14	+2%	+$7.92K	0.07%	148
2025 Q3	$305K	Buy	+629	New	+$293K	0.06%	166

Other funds holding TMO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Atlas Legacy Advisors's TMO Position: Q2 2026 in Review

Atlas Legacy Advisors sold out of Thermo Fisher Scientific (TMO) in Q2 2026, closing a stake of 430 shares — an estimated $211K sold.

Atlas Legacy Advisors first reported a position in TMO in Q3 2025 and held it in 3 quarters. The position peaked at $383K in Q4 2025. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

Atlas Legacy Advisors reported no remaining Thermo Fisher Scientific position as of Q2 2026 after selling out during the quarter.
Atlas Legacy Advisors sold 430 Thermo Fisher Scientific shares in Q2 2026, an estimated $211K.
Atlas Legacy Advisors first reported a position in Thermo Fisher Scientific in Q3 2025 and held it in 3 quarters.
Atlas Legacy Advisors's Thermo Fisher Scientific position peaked at $383K in Q4 2025.
2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Atlas Legacy Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.